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SUMMARY
Although PML-enforced RARA homodimerization allows PML/RARA to bind DNA independently of
its coreceptor RXR, the latter was identified within the PML/RARA complex. We demonstrate that a
PML/RARA mutant defective for RXR binding fails to trigger APL development in transgenic mice,
although it still transforms primary hematopoietic progenitors ex vivo. RXR enhances PML/RARA
binding to DNA and is required for rexinoid-induced APL differentiation. In RA-treated PML/RARA-
transformed cells, the absence of RXR binding results in monocytic, rather than granulocytic, differ-
entiation. PML/RARA enhances posttranslational modifications of RXRA, including its sumoylation,
suggesting that PML-bound sumoylation enzymes target RXRA and possibly other PML/RARA-
bound chromatin proteins, further contributing to deregulated transcription. Thus, unexpectedly,
RXR contributes to several critical aspects of in vivo transformation.INTRODUCTION
Acute promyelocytic leukemia (APL) is caused by the
expression in hematopoietic cells of the PML/RARA onco-
gene. This fusion protein is a potent transcriptional repres-
sor that interferes with gene expression programs involved
in both progenitor self-renewal and terminal myeloid cell
differentiation (Sell, 2005). It was proposed that PML/
RARA homodimerization, through a coiled coil in PML, is
key to transformation, and indeed, forced RARA dimeriza-
tion recapitulates many properties of PML/RARA, includ-
ing corepressor/HDAC recruitment and target gene silenc-
ing (Grignani et al., 1998; Kwok et al., 2006; Licht, 2006;
Lin and Evans, 2000; Lin et al., 1998; Minucci et al., 2000;
Sternsdorf et al., 2006; Zhou et al., 2006). Recent studieshave also demonstrated that specific posttranslational
modifications of PML/RARA, such as sumoylation, are es-
sential for transformation (Zhu et al., 2005). While the ability
of the fusion protein to negatively regulate transcription
appears to be essential for transformation, treatment
with retinoic acid (RA) induces complete remissions (War-
rell et al., 1993), at least in part through reactivation of
PML/RARA-dependent transcription.
The normal RARA receptor can only bind DNA when
coupled to another class of nuclear receptor, the RXRs,
which are the promiscuous partners of many different
class II nuclear receptors (Kastner et al., 1995). Within
these heterodimeric complexes, RXRs can contribute to
repression or activation (Calleja et al., 2006; Kuriyan, 2004),
in part through specific posttranslational modifications,SIGNIFICANCE
Acute promyelocytic leukemia (APL) is caused by translocations always involving a transcription factor, RARA.
Several studies have stressed the importance of translocation-induced RARA dimerization in the transformation
process. Here, we demonstrate that the presence of the RARA heterodimeric partner RXR in the PML/RARA com-
plex is required for leukemogenesis in transgenic mice. RXR greatly facilitates the binding of PML/RARA to DNA,
but titration of RXR by PML/RARA could also contribute to transformation. Drugs that activate RXR relieve PML/
RARA-induced transcriptional repression and trigger APL differentiation, only when RXR is PML/RARA bound.
Finally, in PML/RARA-expressing cells, RXR undergoes a specific modification, sumoylation, which could further
enhance transcriptional repression. Thus, through several distinct mechanisms, RXR is an unsuspected essential
factor in APL pathogenesis.Cancer Cell 12, 23–35, July 2007 ª2007 Elsevier Inc. 23
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RXR Is Required for PML/RARA Transformation in APLsuch as phosphorylation or sumoylation (Choi et al., 2006;
Gianni et al., 2003; Mann et al., 2005; Srinivas et al., 2005;
Tarrade et al., 2005; Zimmerman et al., 2006). While early
experiments had demonstrated that PML/RARA can bind
RXR (Perez et al., 1993), the actual presence of RXR within
the DNA-bound PML/RARA oncogenic complex was only
demonstrated recently (Kamashev et al., 2004). RXR facil-
itates the binding of PML/RARA to widely spaced direct re-
peats (Kamashev et al., 2004), a property that is important
for transformation ex vivo (Zhou et al., 2006). When cou-
pled to activation of cAMP signaling, RXR-specific ligands
(rexinoids) were shown to differentiate APL cells, as well as
many non-APL myeloid human leukemia samples (Altucci
et al., 2005; Benoit et al., 1999). In APL cells, this associa-
tion in fact activates transcription of PML/RARA-specific
target genes, unifying the mechanisms of APL cell differen-
tiation (Kamashev et al., 2004).
We have investigated the role of RXR in the PML/RARA
complex through a variety of ex vivo and in vivo experi-
ments and demonstrate that, while RXR is dispensable
for immortalization of primary hematopoietic progenitors
ex vivo, it is absolutely required for APL development in
transgenic mice. The presence of RXR in the PML/RARA
complex not only facilitates DNA binding, but is also re-
quired for rexinoid-induced differentiation, demonstrating
that RXR is not a silent partner, but a critical determinant
of transformation.
RESULTS
Using structural information from the crystallized RARA/
RXR heterodimer, we had previously identified two posi-
tions in RARA (M379 and T382) that are essential for RXR
binding (Zhu et al., 1999). While in the context of RARA this
mutation abrogates DNA binding, PML-enforced dimer-
ization allows the formation of a PML/RARAM883R,T886R
homodimers/DNA complex, confirming that PML/RAR
binding to DNA does not require RXR (Figure 1A) (Jansen
et al., 1995; Perez et al., 1993). The RXR interaction domain
of RARA is embedded within the ligand-binding domain
and could potentially interfere with ligand-dependent acti-
vation. To demonstrate that PML/RARAM883R,T886R re-
mains a RA-dependent transcriptional activator, we evalu-
ated by quantitative RT-PCR the transcriptional response
to RA of PML/RARA-specific genes, such as tgII (Benedetti
et al., 1996; Zhou et al., 2006), in primary hematopoietic
progenitor cells transduced with PML/RARA or PML/
RARAM883R,T886R (Figure 1B). In contrast to mock-
infected cells, a clear induction of tgII expression was
observed in response to RA administration for both fusion
proteins, establishing that this point mutation does not af-
fect ligand-dependent transcriptional activation. We also
questioned whether PML/RARAM883R,T886R might be
degraded upon exposure to RA, a feature of DNA-binding
and transcriptionally active RARs (Zhu et al., 1999). PML/
RARAM883R,T886R, in sharp contrast to the parental
RARAM379R,T382R, was efficiently degraded upon RA
exposure (Figure 1C). Note that the sumoylation pattern of24 Cancer Cell 12, 23–35, July 2007 ª2007 Elsevier Inc.the PML/RARA mutant was identical to that of PML/RARA
(Figure 1C) and that sumoylation remained arsenic sensi-
tive (data not shown), demonstrating that the inability to
bind RXR does not affect this critical posttranslational
modification (Lallemand-Breitenbach et al., 2001; Zhu
et al., 2005).
Enhanced binding of SMRT onto PML/RARA homo-
dimers was proposed to be the critical event leading to
transcriptional repression of RA target genes and leuke-
mogenesis (Kwok et al., 2006; Lin and Evans, 2000;
Minucci et al., 2000; Sternsdorf et al., 2006; Zhou et al.,
2006). Whether the presence of RXR in this complex af-
fects SMRT binding or its stability upon RA exposure was
never examined. The PML/RARA//RXR complex was
reproducibly more sensitive to RA-induced SMRT dissoci-
ation than the PML/RARA homodimeric complex (Fig-
ure 1D). Indeed, in the presence of RXR, SMRT was com-
pletely dissociated from the complex at a concentration of
200 nM, while the PML/RARA homodimer retained a sig-
nificant SMRT binding, which was maintained even with
RA concentrations greater than 1 mM, consistent with pre-
vious studies (Lin and Evans, 2000; Minucci et al., 2000;
Figure 1D, lower panel; and data not shown). Thus, the
RA dose response of SMRT dissociation from the PML/
RARA//RXR heterotetramer closely resembles the RA
dose response of APL cell differentiation (Quenech’Du
et al., 1998).
We then questioned whether RXR binding would be dis-
pensable for PML/RARA-induced transformation of pri-
mary hematopoietic progenitors ex vivo (Du et al., 1999).
The fusion protein defective for RXR binding induced
a sharp differentiation arrest and allowed indefinite replat-
ing of the colonies (Figure 2A). Yet, subtle differences were
noted between the cells transformed by these two fusion
proteins, as untreated PML/RARAM883R,T886R-trans-
formed cells had more monocytic features on May Grun-
wald Giemsa (MGG) stains or fluorescence-activated cell
sorting (FACS) analysis (greater expression of the Mac1
monocytic antigen than Gr-1, a granulocytic differentiation
marker), when grown in methylcellulose or in liquid cul-
tures (Figure 2B). PML/RARAM883R,T886R was usually
expressed at 2- to 3-fold higher levels than the parental
fusion protein (Figure 1C). We examined whether PML/
RARAM883R,T886R-transformed cells would retain RA
sensitivity. In methylcellulose, a dramatic response to RA
was manifested by a sharp decrease in the number of
dense colonies, identical to the one found in PML/RARA-
transformed cells (Figure 2B). Interestingly, after 8 days
in methylcellulose in the presence of RA, PML/RARA-
transformed cells yielded granulocytes, while PML/
RARAM883R,T886R-transformed ones differentiated into
monocytes, as assessed by both MGG staining and
expression of the myeloid antigens Mac1 and Gr-1 (Fig-
ure 2B). Similarly, in liquid culture, PML/RARA-trans-
formed cells differentiated into both monocytes and gran-
ulocytes, while PML/RARAM883R,T886R-transformed
cells showed only monocytic features upon RA treatment.
This unexpected monocytic differentiation was observed
with three different transductions, including one where
Cancer Cell
RXR Is Required for PML/RARA Transformation in APLFigure 1. Functional Characterization of a PML/RARA Mutant Defective for RXR Binding
(A) Gel shift analysis with a DR5 RARE of different RARA derivatives with or without RXR, as indicated.
(B) Quantitative PCR analysis of a PML/RARA-specific gene, tgII (Benedetti et al., 1996), in primary hematopoietic progenitor cells transduced by
PML/RARA or PML/RARAM883R,T886R after a 15 hr exposure to 106 M RA. Means ± standard deviation (SD).
(C) (Upper panel) Cos cells transiently transfected with RARA or RARAM379R,T382R, treated overnight with 106 M RA. (Lower panel) Cells analyzed
in (B), with or without retinoic acid. Note that defective RXR binding does not affect the sumoylation pattern of PML/RARA.
(D) RXR modulates binding of SMRT to the PML/RARA DNA complex. (Lower panel) Quantifications of the critical lanes (1, 5, 6, and 10) of the
autoradiogram. Note that 200 nM RA restores the baseline profile of the PML/RARA//RXR complex, but not of the PML/RARA complex.the levels of expression of the wild-type or mutant fusions
were similar.
RXR is normally a transcriptionally silent partner of the
RXR/RAR heterodimer, due to RXR subordination (Ger-
main et al., 2002). Yet, the rexinoid/cAMP association was
shown to induce a robust transcriptional activation of RAtarget genes, such as RARB, through desubordination of
the transcriptional activation domain of RXR (Altucci et al.,
2005; Kamashev et al., 2004). Interestingly, in the context
of cytokine-treated cells, in methylcellulose or in liquid cul-
tures, rexinoids triggered some differentiation of PML/
RARA-transformed cells, while cAMP on itself did not,Cancer Cell 12, 23–35, July 2007 ª2007 Elsevier Inc. 25
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RXR Is Required for PML/RARA Transformation in APLFigure 2. Role of RXR Binding in PML/RARA-Induced Transformation and Response to RA or Rexinoids
(A) Transduction of PML/RARA, or its RXR-binding-defective mutant, both transform primary hematopoietic progenitors. Replating assay in methyl-
cellulose. Means ± standard deviation (SD).26 Cancer Cell 12, 23–35, July 2007 ª2007 Elsevier Inc.
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RXR Is Required for PML/RARA Transformation in APLand the rexinoid/cAMP association was identical to rexi-
noids alone (Figure 2C and data not shown). Rexinoid-trig-
gered differentiation was not as complete than the one
triggered by RA and was not associated with a decrease
in colony numbers (data not shown). It was essentially
manifested by a reproducible decrease in Kit expression,
with an increase in Mac1 staining and some morphologi-
cal changes toward greater maturity (Figure 2C). The rexi-
noid/cAMP association led to the synergistic degradation
of PML/RARA, but not PML/RARAM883R,T886R (Fig-
ure 2C), suggesting that, in that setting, transcriptional
derepression by rexinoids contributes to the differentia-
tion process and that full PML/RARA degradation is not
a prerequisite for differentiation. Importantly, PML/RAR-
AM883R,T886R-transformed cells were completely unre-
sponsive to rexinoids and also failed to degrade the fusion
protein upon exposure to the association of rexinoid and
cAMP. Finally, as expected, addition of rexinoids to reti-
noids yielded additive effects (whether cAMP was present
or not), as previously noted in other transformed myeloid
cells (Shiohara et al., 1999), and this only in cells trans-
formed by PML/RARA, but not its mutant (data not shown).
Altogether, while RXR binding to PML/RARA is dispens-
able for ex vivo transformation, it modulates the pheno-
type of the transformed cells and is required for response
to rexinoids.
To further address the importance of RXR binding by
PML/RARA in the leukemogenic process in vivo, we gen-
erated PML/RARAM883R,T886R transgenic mice under
the transcriptional control of the MRP8 promoter (Brown
et al., 1997; Zhu et al., 2005). Eight founders were ob-
tained, which all expressed PML/RARA (Figures 3A, 3D,
and 3E). Serial analyses of the peripheral blood demon-
strated an increase in the proportion of normal myeloid
elements in six of the eight lines (Figure 3B). Enlargement
of the spleen was repeatedly noted in 30% of the founders
or offspring, with the disappearance of the normal lym-
phoid follicles. This was accompanied by a very dense
bone marrow, with a clear predominance of myeloid cells
in MGG staining or FACS analysis of marrow aspirates
(Figures 3C and 3F). Rare proliferations of hematopoietic
cells were found in the liver. These myeloproliferative
diseases were transplantable with a low efficiency and
a long latency. Strikingly, not a single APL was observed,
despite a more than 3 years follow-up of founders, their
offspring, or their engrafted marrows into irradiated syn-
geneic recipients (Figure 3A). At large, the levels of PML/
RARAM883R,T886R expression in the bone marrow
were slightly higher than those previously observed in
PML/RARA transgenics (Zhu et al., 2005), despite signifi-
cant overlaps (Figure 3E and data not shown). Note that,
in contrast to cathepsin G promoter PML/RARA trans-
genic, with the promoter used here, higher levels of PML/
RARA expression are usually associated with a higher in-
cidence of APL (Westervelt et al., 2003; Zhu et al., 2005).Expression of the fusion protein in marrows of PML/RAR-
AM883R,T886R transgenics were lower than in retrovirally
transduced progenitor cells (Figure 3E, left part). In keep-
ing with the observations in methylcellulose cultures,
several transgenics expressing high levels of PML/RAR-
AM883R,T886R protein (lines 14, 44) had a clear excess
of monocytes in the peripheral blood (Figure 3B) and in
the bone marrow (Figure 3F). Interestingly, MRP8-PML/
RARA transgenics exhibit a complex skin disease (Brown
et al., 1997; Hansen et al., 2003; Zhu et al., 2005). The
severity of these lesions is directly proportional to PML/
RARA expression and independent of its K160 residue
(S. Kogan, personal communication, and Zhu et al., 2005).
Intriguingly, none of the founder mice or their offspring
ever exhibited any type of skin lesion (Figure 3G). Alto-
gether, PML/RARAM883R,T886R transgenic mice only
develop a mild myeloproliferative syndrome (Kogan
et al., 2002) that never evolves toward full-blown APL.
Many of the features of PML/RARAM883R,T886R de-
scribed so far could result from a lower affinity for its DNA-
binding sites. In the absence of RXR, both PML/RARA or
PML/RARAM883R,T886R bound DR5, DR8, or DR12 re-
sponse elements (Figures 1A and 4A) (Kamashev et al.,
2004). Coexpression of RXR dramatically increased the
binding efficiency of PML/RARA, but not of PML/RAR-
AM883R,T886R to all three elements (Figure 4A). To di-
rectly investigate the consequence of this difference in
DNA-binding affinity observed in gel shift analysis, mouse
embryo fibroblasts (MEFs) in which the three RARs were
excised and in which any RA-induced transcriptional
modification is dependent on the transduced receptor
(Altucci et al., 2005) were transduced by PML/RARA or
PML/RARAM883R,T886R. Despite a higher expression
of the mutant fusion by western blot (Figure 4B), only
PML/RARA reproducibly activated the expression of two
(rarb and tgII) of the three primary target genes tested
(rarb, cyp26A, and tgII), PML/RARAM883R,T886R being
completely inactive in this assay (Figure 4B and data not
shown). Contrarily to the prevailing model, PML/RARA ex-
pression did not induce significant changes in the baseline
levels of these three target genes (data not shown). That
the levels of the two fusion proteins in fibroblasts were
lower than those in transduced hematopoietic cells may
explain why tgII activation was observed in one system
(Figure 1B), but not the other (Figure 4B). An alternative
explanation could be that the corepressor/coactivator
content of those two types of cells is very different or
that the epigenetic chromatin environment of the PML/
RARA binding site(s) within the tgII promoter significantly
differs between MEFs and transformed primary hemato-
poietic progenitors. In that respect, while tgII may be in-
duced several hundred folds in APL cells, its amplitude
of induction in MEFs is only 7-fold (Benedetti et al.,
1996; Zhou et al., 2006). Finally, in transient transfections
where PML/RARA blunts the transcriptional response of a(B) Response to RA (106 M) treatment for a week in methylcellulose or 3 days in liquid culture of transduced cells at passage 3.
(C) Response to rexinoids (BMS 649, 3 mM) in the same conditions as above. (Right) Western blot analysis after an overnight treatment with rexinoids
and/or cAMP.Cancer Cell 12, 23–35, July 2007 ª2007 Elsevier Inc. 27
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RXR Is Required for PML/RARA Transformation in APLFigure 3. PML/RARAM883R,T886R Transgenic Mice Do Not Develop APL
(A) Summary of the mouse data. Transgenics (founders or offspring) that developed a large spleen are indicated, as well as primary grafts of trans-
genic bone marrow. None of these mice ever developed APL.
(B) Mean values of blood count from the indicated number of mice in each line.
(C) Histologic features of a normal mice and a representative PML/RARAM883R,T886R with spleen enlargement. Note the very dense bone marrow
and the destructured architecture of the spleen.
(D) Immunofluorescence of transgenic bone marrow demonstrating high PML/RARA expression in granulocytes.
(E) Western blot analysis of bone marrow extracts from mice (founders or offspring) in the different transgenic lines. (Left panel) Comparison
between PML/RARA-transduced hematopoietic progenitors (MC), two representative PML/RARA transgenic (PR) (Zhu et al., 2005), and the28 Cancer Cell 12, 23–35, July 2007 ª2007 Elsevier Inc.
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RXR Is Required for PML/RARA Transformation in APLFigure 4. RXR Binding Increases the DNA-Binding Affinity of PML/RARA
(A) Gel shift analysis. Binding of the normal or mutant fusion protein, with or without RXR, to various AGGTCA direct repeat (DR) response elements
(Kamashev et al., 2004) is shown.
(B) (Left panel) quantitative RT-PCR analysis of RA target genes in RARs/ MEFs stably transduced by the indicated fusion proteins and treated
overnight with 106 M RA (mean of two independent transductions). Western blot analysis of these cells is shown in the right panel.
(C) ChIP analysis of PML/RARA or PML/RARAM883R,T886R binding to the cloned RARB promoter in transfected Cos cells, expressed as increase
over nonspecific binding. Means ± standard deviation (SD).
(D) Model for the enhancing effect of RXR binding on PML/RARA DNA-binding properties. Strong interactions are noted by a red broken line, while
weak ones are indicated by a green one.RA-sensitive reporter gene (RARE-3-Tk-Luc) (de The´ et al.,
1991), the mutant was much less potent than the parental
fusion in blocking RA response (data not shown). To di-
rectly demonstrate that in vivo PML/RARAM883R,T886R
binds less efficiently to response elements in a cellularcontext, we performed a chromatin immunoprecipitation
(ChIP) experiment. Cos cells were transfected with the
RARB promoter, which contains a well-characterized
RA-responsive sequence (de The´ et al., 1990) activated by
PML/RARA (Zhou et al., 2006; Figure 4C), together withPML/RARAM883R,T886R transgenic line 85. (Right panel) All eight lines of PML/RARAM883R,T886R transgenics and a littermate negative control.
A PML/RARA cleavage product is occasionally observed (Lane and Ley, 2003).
(F) Flow cytometry analyses of bone marrows from normal, APL, and two distinct PML/RARAM883R,T886R mice with myeloproliferative disease.
(G) In contrast to PML/RARA transgenic mice (Zhu et al., 2005), PML/RARAM883R,T886R mice never develop a skin defect.Cancer Cell 12, 23–35, July 2007 ª2007 Elsevier Inc. 29
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RXR Is Required for PML/RARA Transformation in APLexpression vectors for PML/RARA or PML/RAR-
AM883R,T886R and RXR. Identical levels of RXR and the
fusion proteins were obtained (data not shown). After im-
munoprecipitation of the PML/RARA-DNA complex and
quantification of the precipitated RARB sequence by
quantitative PCR, 4-fold higher levels of DNA were consis-
tently recovered with PML/RARA compared to PML/RAR-
AM883R,T886R (Figure 4C). Although of potential interest,
ChIP analysis of endogenous PML/RARA target genes
was not attempted in primary bone marrow cells because
of the very low level of PML/RARA expression and the low
affinity of PML or RARA antibodies. Altogether, these stud-
ies strongly support the idea that the greater DNA-binding
efficiencies of PML/RARA//RXR heterotetramers, com-
pared to PML/RARA homodimer, contribute to a more
potent gene regulation (Figure 4D).
We then questioned whether RXR binding onto PML/
RARA could result in changes in RXR stability or posttrans-
lational modifications. Indeed, RXRs may be phosphory-
lated, ubiquitinylated, or sumoylated, phosphorylation
occurring upon RA exposure or MAPK or JNK activation
(Choi et al., 2006; Gianni et al., 2003; Mann et al., 2005;
Srinivas et al., 2005; Takano et al., 2004; Zimmerman
et al., 2006). We first compared the expression of RXRA,
the major RXR isoform expressed in myeloid cells (Tasch-
ner et al., 2007), in primary hematopoietic progenitors
transformed by PML/RARA or PML/RARAM883R,T886R.
A striking increase in the abundance of low-mobility RXRA-
reactive protein species was noted, in PML/RARA-trans-
formed cells only, while RXRA expression was often mod-
erately increased. In every experimental system tested
(primary hematopoietic progenitors, U937 cells, retrovir-
ally transduced MEFs or NB4 cells), PML/RARA triggered
a 3- to 10-fold increase in the abundance of this modified
RXRA protein (Figure 5A and data not shown). Similarly,
in transfected cells, PML/RARA stabilized RXRA (moder-
ately in HeLa and massively in CHO cells) and further en-
hanced the abundance of this low-mobility form (Figure 5B,
upper part; and data not shown). No quantitative or quali-
tative change in RXRB expression was noted upon PML/
RARA expression (data not shown).
PML or PML/RARA are extensively sumoylated proteins
(Lallemand-Breitenbach et al., 2001; Muller et al., 1998;
Zhu et al., 2005). The sumoylation machinery recruited
onto the PML moiety of PML/RARA (Lallemand-Breiten-
bach et al., 2001; Zhu et al., 2005) might also enhance
sumoylation of PML/RARA-bound RXRA. In transfected
HeLa or CHO cells, coexpression of sumo1, but not
sumo2, increased the abundance of the low-mobility
RXRA-reactive protein, an effect dramatically enhanced
in the presence of PML/RARA, (Figure 5B, upper panel).
These observations suggest that the slow-migrating form
of RXRA is an RXRA-sumo conjugate, although an initial
transient sumoylation could trigger a subsequent ubiquiti-
nation or phosphorylation (Huang et al., 2003; Ulrich,
2005). We then transiently expressed PML/RARA together
with RXRA, Ubc9, YFP-sumo1, or YFP-sumo2 in HeLa
cells and immunoprecipitated RIPA-soluble proteins.
Expression of YFP-sumo1 and, to a lesser extent, YFP-30 Cancer Cell 12, 23–35, July 2007 ª2007 Elsevier Inc.sumo2, yielded novel RXRA-reactive proteins (Figure 5B,
bottom panel), which were immunoprecipitated with anti-
RXRA or GFP antibodies (Choi et al., 2006) and whose
abundance was reproducibly increased by PML/RARA
expression (Figure 5B, bottom panel). In this experiment,
PML/RARA did not induce significant RXRA stabilization,
allowing significant comparison of the sumoylated RXRA
species’ abundance. These experiments directly demon-
strate that PML/RARA enhances RXRA sumoylation.
We finally investigated which domains of PML/RARA
were required for enhancement of RXRA modification.
To this end, we expressed in both primary hematopoietic
cells or MEFs a number of PML/RARA mutants (Figure 5C
and data not shown). The arsenic-induced K160 sumoyla-
tion site in PML (Lallemand-Breitenbach et al., 2001; Zhu
et al., 2005) was not only dispensable for RXRA sumoyla-
tion but actually reproducibly enhanced it (Figure 5C and
data not shown). In contrast, disrupting the PML RING fin-
ger in PML/RARA (C88SP89R) abrogated the enhanced
modification of RXRA, while a point mutation in the RA-
binding domain of the RARA moiety of PML/RARA (Shao
et al., 1997) did not. As expected, overexpression of
RARA did not change the baseline modification of RXRA
(Figure 5C). Altogether, PML/RARA-enhanced RXRA
modification requires tethering onto RXR of the PML func-
tional domains required for PML sumoylation (Duprez
et al., 1999; Kamitani et al., 1998; Lallemand-Breitenbach
et al., 2001).
DISCUSSION
Here we demonstrate the essential role of RXR in PML/
RARA-induced APL leukemogenesis and outline some of
the mechanisms involved. While PML/RARA may bind
DNA in the absence of RXR, the heterotetramer formed
in its presence has a much greater DNA-binding affinity
(Figures 4A and 4D), which likely accounts for its more
potent biological properties. At the molecular level, the
presence of four DNA binding sites that all recognize the
AGGTCA core motif likely explains the cooperative bind-
ing ex vivo or in vivo, as the DNA-binding domains not
interacting with the specific AG(G/T)TCA half-sites may
also contribute to the stability of the complex through
non-sequence-specific interactions with DNA. We had
previously demonstrated that the binding of PML/RARA
to very widely spaced half-sites, which is required for
transformation (Zhou et al., 2006), was greatly favored in
the presence of RXR (Kamashev et al., 2004). Finally, DR1
response elements are only recognized by the PML/
RARA//RXR heterotetramer, but not by PML/RARA homo-
dimers, presumably because of steric hindrance (Jansen
et al., 1995; Kamashev et al., 2004; Perez et al., 1993).
Hence, reduced DNA-binding affinity or a more restricted
binding site repertoire likely plays a critical role in the
weaker phenotype of the mutant.
The greater biological effects of PML/RARA, when com-
pared to its defective mutant, does not reflect a higher
level of protein expression, as PML/RARAM883R,T886R
was usually expressed at higher levels than the parental
Cancer Cell
RXR Is Required for PML/RARA Transformation in APLFigure 5. PML/RARA Enhances Posttranslational Modifications of RXRA
(A) Whole-cell extracts from immortalized bone marrow progenitors, MEFs or U937 cells (Grignani et al., 1993), were probed with an anti-RXRA (upper
panel) or RARA (lower panel). The amounts of extracts loaded were adjusted for similar RXRA expression. The modified RXR species are indicated
by an asterisk. The addition of zinc to induce PML/RARA expression in U937 cells is indicated by + or ; MT refers to the metallothionein promoter
control.
(B) HeLa or CHO cells were transfected with the indicated constructs and probed for RXRA expression. (Upper panel) PML/RARA expression stabi-
lizes RXRA and increases its modified form (asterisk). Different amounts of whole-cell extracts were analyzed to allow comparison of the efficiency
of RXRA modification. (Bottom panel) PML/RARA enhances conjugation of RXRA to YFPsumo1. RIPA extracts of transfected HeLa cells were
immunoprecipitated with anti-RXRA (left) or anti-GFP (right). RXRA and YFP-sumo/RXRA are indicated.
(C) RXRA posttranslational modification (asterisk) in primary hematopoietic progenitors transduced with the indicated PML/RARA mutants.
(D) Model of PML/RARA-mediated tethering of the PML-bound sumoylation machinery onto the chromatin environment.fusion. Moreover, the pattern of posttranslational modifi-
cations, such as sumoylation, was identical between the
parental and the mutant protein (Figure 1C). We favor
the idea that the greater expression of the mutant fusion
could result from both its reduced toxicity and/or its
greater stability. Both of these features may reflect its
lower affinity for DNA, as DNA binding was shown to be
a critical determinant of RARA degradation (Zhu et al.,
1999). PML/RARA is an extremely toxic protein in fibro-
blasts (Lavau et al., 1996), and in our hands, PML/RARA
expression remained very low whatever the multiplicity
of infection used, while that of PML/RARAM883R,T886R
could reach 50 times that of the parental protein with
repeated courses of retroviral infection (data not shown).Note, however, that in PML/RARA transgenics very similar
levels of expression were obtained (Figure 3E), allowing a
direct and relevant comparison of the leukemogenic prop-
erties of the wild-type and mutant protein in vivo.
The consequences of the RXR-binding mutation were
different in the two biological systems analyzed here.
While both PML/RARA and its mutant efficiently trans-
formed hematopoietic progenitors ex vivo, PML/RAR-
AM883R,T886R transgenic mice developed a mild nonfa-
tal myeloproliferative disease, which did not transplant
well, but never APL. This discrepancy is not unprece-
dented: RARA was shown to immortalize primary hemato-
poietic progenitors (Du et al., 1999), while transgenic mice
expressing several types of dominant-negative RARACancer Cell 12, 23–35, July 2007 ª2007 Elsevier Inc. 31
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several self-dimerizing RARA were shown to efficiently
promote transformation ex vivo, while this process is
very inefficient in transgenic mice (Kwok et al., 2006;
Sternsdorf et al., 2006; Zhou et al., 2006; Zhu et al.,
2005). Thus, the ex vivo and in vivo models of PML/
RARA-induced transformation do not have identical ge-
netic requirement.
RXR-dependent signaling regulates many important
aspects of hematopoiesis (Johnson et al., 1999; Rusten
et al., 1996; Taschner et al., 2007). PML/RARA-triggered
transformation was suggested to involve RXR titration
away from its other partners (Kastner et al., 1992; Perez
et al., 1993). Note that, in the context of RARA-triggered
ex vivo transformation (Du et al., 1999), mutation in the
DNA-binding domain abolished ex vivo transformation
(data not shown), implying that titration of RXR is not the
sole basis for the phenotype, as suggested in other sys-
tems (Kastner et al., 1995; Saitou et al., 1995). Our
approach, in contrast to those using extinction of RXR
expression, allows a direct assessment of the conse-
quences of RXR titration by PML/RARA. Ex vivo and to
a lesser extent in vivo, RXR binding by the fusion protein
modulates the phenotype of undifferentiated or RA-
differentiated cells: PML/RARAM883R,T886R-transformed
cells had monocytic features and differentiated into typical
monocytes (Figure 2B; Figures 3B and 3F). Interestingly, in
normal myeloid cells, extinction of RXRA expression is
required for granulocytic differentiation, while conversely,
enforced RXRA expression favored monocytic differentia-
tion (Taschner et al., 2007), suggesting that RXRA titration/
degradation by PML/RARA could contribute to the granulo-
cytic differentiation of RA-treated APL cells. Similarly, the
skin phenotype of PML/RARA transgenics, which bears
many similarities with that of RXRs/ mice (Li et al.,
2000), was never observed in any of the PML/RAR-
AM883R,T886R transgenics (Figure 3G), even in lines with
high transgene expression and myeloproliferative disease.
Altogether, these observations argue for a contribution of
RXR titration to PML/RARA-dependent events, including
RA-induced differentiation.
Recent evidence has demonstrated that RXR is not
a transcriptionally silent partner within the RXR/RARA or
PML/RARA//RXR complexes. In fact, upon dissociation
of SMRT from RARA, induced by cAMP-triggered PKA ac-
tivation, rexinoids can become potent transcriptional acti-
vators of RARA or PML/RARA target genes and trigger APL
cell differentiation (Altucci et al., 2005; Benoit et al., 1999;
Kamashev et al., 2004). That RXR binding to PML/RARA
is required for rexinoid-induced differentiation is fully con-
sistent with our previous observations. Unexpectedly,
however, the rexinoid/cAMP combination induced neither
full differentiation nor growth arrest in PML/RARA-trans-
formed cells in methylcellulose assays, liquid culture, or
APL mice (Guillemin et al., 2002) (Figure 2; data not shown).
As rexinoids were only shown to trigger terminal differenti-
ation in human cells (Altucci et al., 2005; Benoit et al.,
1999), mouse RXRA could be a weaker activator than its
human counterpart.32 Cancer Cell 12, 23–35, July 2007 ª2007 Elsevier Inc.We demonstrate that PML/RARA promotes posttrans-
lational modifications of RXRA, including sumoylation,
which triggers transcriptional repression for RXRA as for
many other transcription factors (Choi et al., 2006; Hay,
2005; Verger et al., 2003). We cannot rule out that RXRA
binding onto PML/RARA does not also promote other
modifications, such as phosphorylations, which trigger
RXRA transcriptional activation, nuclear export, and pro-
teasome-dependent degradation (Gianni et al., 2003;
Srinivas et al., 2005; Zimmerman et al., 2006). Yet, arse-
nic-induced RXRA phosphorylation (Mann et al., 2005;
Tarrade et al., 2005) yielded a distinct pattern of modifica-
tion (data not shown). That PML/RARA can enhance
RXRA sumoylation suggests that fusion of PML to RARA
tethers an active sumoylation machinery in the vicinity
of PML/RARA chromatin-binding sites (Figure 5D), con-
ceivably modifying not only RXRA, but also neighboring
chromatin proteins such as histones, corepressors, and
coactivators, whose functions are tightly regulated by
sumoylation (Hay, 2005). Our observations thus raise the
prospect that dysregulated sumoylation induced by
PML/RARA may contribute to altered gene expression
and contribute to APL pathogenesis. Unfortunately, this
hypothesis cannot be directly tested ex vivo, because
RXR binding to PML/RARA is dispensable in that setting.
RING finger mutations that impair RXRA sumoylation
(Figure 5C) also affect sumoylation of PML/RARA K160
(Kamitani et al., 1998; and data not shown), which is criti-
cal for ex vivo and in vivo transformation (Zhu et al., 2005).
More elaborate strategies using in vivo substitution of
RXRA by a nonsumoylatable mutant would be required
to establish the in vivo importance of RXRA sumoylation
in APL pathogenesis. Altogether, RXR facilitates PML/
RARA-induced transformation through several different
mechanisms but also participates in the differentiation
response, identifying this coreceptor as an unsuspected
key member of the oncogenic complex.
EXPERIMENTAL PROCEDURES
Retroviral Transductions
The cDNA encoding PML/RARA corresponds to the bcr1 breakpoint
and includes the alternatively spliced exon 5 as well as the PML nls
(de The´ et al., 1991). The two mutations that abolish RXR binding to
RARA were transferred from RARAM379R/T382R into PML/RARA
(Zhu et al., 1999). Infection of lineage-depleted bone marrow from
5-fluorouracil-treated C57BL/6 mice, culture, and G418 selection of
the transduced progenitors cells in methylcellulose with stem cell
factor, IL3, IL6, and GM-CSF were performed exactly as previously de-
scribed (Du et al., 1999). After a week, neomycin-selected cells were
recovered from methylcellulose and either analyzed (FACS, MGG
staining, immunofluorescence, and western blot) or replated at a den-
sity of 10,000 cells per dish. Cells were serially replated until they
stopped growing. Cell growth in liquid culture was assessed in RPMI
1640 medium supplemented with IL3, IL6, and SCF.
Protein Analyses
Electrophoretic shift analyses were performed as previously described
(Kamashev et al., 2004; Zhu et al., 1999), using extracts from Cos-
transfected cells, bacterially produced SMRT, and the DR5 RA
response element (RARE) from the RARB gene (de The´ et al., 1990)
or canonical response elements with various spacings, as previously
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RXR Is Required for PML/RARA Transformation in APLdescribed (Kamashev et al., 2004). When analyzing the effect of RA
on the interaction between the SMRT corepressor and the different
PML/RARA complexes, RA treatment was performed directly in the
transfected cells used to prepare the extracts. Western blotting
was performed using an antibody RP115 kindly provided by
P. Chambon. Anti-RXRA were from Santa-Cruz, while anti-RXRB
were from Abcam.
ChIPs were performed in CHO or Cos cells transfected with 100 ng
of a 5 kb fragment of theRARB promoter (de The´ et al., 1990) and 50 ng
of PSG5-RXRA and PSG5-PML/RARA or -PML/RARAM883R,T886R.
Immunoprecipitation was then performed using an Active Motif ChIP
kit and a cocktail of anti-PML monoclonals. Quantitative PCR was per-
formed on the rescued DNA using primers encompassing the RARE
and a specific probe (available upon request). Results were expressed
as fold induction over background in the absence of PML/RARA
expression. Immunoprecipitations were performed as previously de-
scribed (Zhu et al., 1999), using anti-RXRA or anti-GFP antibodies.
Immortalized RARs/ MEFs (Altucci et al., 2005) were infected by
retroviruses expressing various PML/RARA derivatives, as described
before (Zhou et al., 2006). Quantitative RT-PCR was performed using
Light-cycler technology (Roche) and commercially available primers
and probes from the rarb, cyp26a, and tgII genes (Applied Biosys-
tems). Rexinoids (BMS 649) were used at a concentration of 3 mM.
8-(4-chlorophenylthio)adenosine 3-50 cyclic monophosphate (8-CPT-
cAMP) was used at a concentration of 2.104 M.
Transgenic Mice
PML/RARA was expressed using the MRP8 promoter (Brown et al.,
1997) in B6/CBA F1 hybrids. Mice were kept under SPF conditions
and used under protocols approved by the Institutional Animal Care
and Use Committee (CREEA4). Hematological disorders, such as
splenomegaly, were never observed in nontransgenic littermates. Eight
PML/RARAM883R,T886R transgenic lines expressing the fusion pro-
teins by both western blot and immunofluorescence were obtained.
Myeloproliferation was defined by the association of splenomegaly
(spleen larger than 150 mg) with highly hyperplastic marrow, in the
absence of significant differentiation abnormalities (Kogan et al.,
2002). F0 founders were sacrificed, and phenotypes were observed
in offspring (when available) or primary grafts in irradiated syngeneic
recipients. Blood cell counts were performed with a Celldyn 3700
counter (Abbott Diagnostic). Bone marrow and pathology analyses
were performed as before (Lallemand-Breitenbach et al., 1999).
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